Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Aug 12;9(15):3754-3765.
doi: 10.1182/bloodadvances.2024015274.

Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma

Alexey V Danilov  1 , Swetha Kambhampati Thiruvengadam  1 , Kim Linton  2 , Karen Cumings  3 , Viktor Chirikov  3 , Alex Mutebi  4 , Savreet Bains Chawla  4 , Anindit Chhibber  4 , Fernando Rivas Navarro  5 , Felipe Marques Gonçalves  4 , Anthony Wang  6 , Zhijie Ding  4 , Abualbishr Alshreef  6 , Elena Favaro  5 , Daniela Hoehn  4 , Anna Sureda  7
Affiliations
Clinical Trial

Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma

Alexey V Danilov et al. Blood Adv. .

Abstract

This matching-adjusted indirect comparison evaluated the efficacy of epcoritamab vs standard of care (SOC), mosunetuzumab, or odronextamab, and assessed safety vs mosunetuzumab and odronextamab. Individual patient-level data from the EPCORE NHL-1 follicular lymphoma (FL) cohort for epcoritamab were used with pooled data from SCHOLAR-5 for SOC (mostly chemoimmunotherapy [CIT]), and aggregate data from GO29781 for mosunetuzumab and ELM-2 for odronextamab. Trial populations were match-adjusted using propensity score weights for key baseline characteristics. Compared with SOC/CIT, epcoritamab provided significantly higher response rates (overall response rate [ORR], 90.9% vs 56.8%; P < .001; complete response [CR] rate, 73.7% vs 32.0%; P < .001). Epcoritamab showed numerically higher ORR (90.9% vs 80.0%; P = .067) and CR rate (72.8% vs 60.0%; P = .159) vs mosunetuzumab. Epcoritamab provided significantly higher ORR (91.5% vs 80.5%; P = .026) and numerically lower CR rate (67.5% vs 73.4%; P = .428) vs odronextamab. Epcoritamab did not have any grade ≥3 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS; any grade) events compared with CRS (grade ≥3) in 2.2% and 3.9% and ICANS in 4.4% and 0.8% of patients treated with mosunetuzumab and odronextamab, respectively (P < .001). In addition to being a convenient subcutaneous option, epcoritamab showed significantly superior response rates and survival outcomes vs SOC/CIT among patients with relapsed or refractory FL after ≥2 systemic therapies. Epcoritamab also exhibited clinically relevant, numerically higher ORRs and demonstrated improved safety for CRS (grade ≥3) and ICANS vs mosunetuzumab or odronextamab. These trials were registered at www.ClinicalTrials.gov as #NCT03625037, #NCT02500407, and #NCT03888105.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: A.V.D. reports consulting fees from AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech, Genmab, Incyte, Janssen, Lilly Oncology, MEI Pharma, Merck, MorphoSys, and Nurix, and research funding from AbbVie, AstraZeneca, Bayer Oncology, Bristol Myers Squibb, Cyclacel, MEI Pharma, and Nurix. S.K.T. reports research funding from Genentech, Genmab, Ipsen, and ADC Therapeutics; consultancy for AbbVie; and advisory board participation for Ipsen. K.L. reports consulting or advisory roles for AbbVie, Roche, Genmab, Kite/Gilead, BeiGene, Bristol Myers Squibb, and Celgene; honoraria from AbbVie, Celgene, Hartley Taylor, and Roche; research grants from Takeda, Roche, Genmab, and AbbVie; and support to attend meetings from Celgene and Genmab. K.C. and V.C. are employees of OPEN Health, which received funding support from Genmab to conduct the research. A.M., S.B.C., F.R.N., F.M.G., Z.D., and E.F. are employees of and hold stock in Genmab. A.C. and D.H. are former employees of Genmab. A.W. and A.A. are employees of and hold stock in AbbVie. A.S. reports consultancy for Takeda, Bristol Myers Squibb/Celgene, Novartis, Janssen, Merck Sharp & Dohme, Amgen, GlaxoSmithKline, Sanofi, Kite, and Mundipharma; honoraria from Takeda, Bristol Myers Squibb/Celgene, Novartis, Janssen, Merck Sharp & Dohme, Amgen, GlaxoSmithKline, Sanofi, and Kite; membership on an entity’s board of directors or advisory committees for Takeda, Bristol Myers Squibb/Celgene, Novartis, Janssen, Amgen, Bluebird, Sanofi, and Kite; travel expenses from Takeda, Bristol Myers Squibb/Celgene, and Roche; research funding from Takeda; and speakers' bureau participation for Takeda, Bristol Myers Squibb/Celgene, Novartis, Janssen, Merck Sharp & Dohme, Amgen, GlaxoSmithKline, Sanofi, and Kite.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Response outcomes of epcoritamab vs comparators. Unadjusted and adjusted ORR and CR rates with ORs (95% CI) for (A) epcoritamab vs SOC/CIT; (B) epcoritamab vs mosunetuzumab; and (C) epcoritamab vs odronextamab.
Figure 2.
Figure 2.
Survival outcomes of epcoritamab vs SOC/CIT. (A) PFS; (B) OS. Comparisons of survival outcomes for epcoritamab vs SOC/CIT were adjusted to account for any reported impact of COVID-19.
Figure 3.
Figure 3.
Survival outcomes of epcoritamab vs mosunetuzumab. (A) PFS; (B) OS. Comparisons of survival outcomes for epcoritamab vs mosunetuzumab were adjusted to account for any reported impact of COVID-19.
Figure 4.
Figure 4.
Survival outcomes of epcoritamab vs odronextamab. (A) PFS; (B) OS.
See this image and copyright information in PMC

References

    1. Cahill KE, Smith SM. Follicular lymphoma: a focus on current and emerging therapies. Oncology (Williston Park) 2022;36(2):97–106. - PMC - PubMed
    1. Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of non-Hodgkin's lymphoma. Med Sci (Basel) 2021;9(1):5. - PMC - PubMed
    1. Oerlemans S, Issa DE, van den Broek EC, et al. Impact of therapy and disease-related symptoms on health-related quality of life in patients with follicular lymphoma: results of the population-based PHAROS-registry. Eur J Haematol. 2014;93(3):229–238. - PubMed
    1. Kanters S, Ball G, Kahl B, et al. Clinical outcomes in patients relapsed/refractory after ≥2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis. BMC Cancer. 2023;23(1) - PMC - PubMed
    1. Skarbnik AZ, Patel K. Treatment selection for patients with relapsed or refractory follicular lymphoma. Front Oncol. 2023;13 - PMC - PubMed

MeSH terms

Substances

Associated data